Drug Trial Radar · NCT05420467
A Study for the Adjuvant Treatment of Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jul 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,413
Planned (sponsor's estimate)
Start
Jul 10, 2022
Primary completion
Jul 10, 2027
Study completion Dec 20, 2027
Sponsor
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Studies on postoperative adjuvant albumin paclitaxel in domestic breast cancer patients are less reported, especially in large samples, and more studies focus more on the safety and tolerability of albumin paclitaxel use. Head-to-head studies of white violet and docetaxel are not supported by data at this time, but some studies have shown that docetaxel-induced long-term Other adverse effects such as myelosuppression, hepatotoxicity and hypersensitivity reactions can have a serious impact on quality of life. Therefore, this study aims to analyse the efficacy and safety of albumin paclitaxel and docetaxel in the adjuvant treatment of breast cancer in a large randomized controlled trial, and to further analyse the efficacy and safety of albumin paclitaxel in combination with chemotherapy for postoperative breast cancer in different subtypes of breast cancer patients, in order to obtain more realistic data and provide new treatment options for breast cancer patients.
Conditions
- Breast Cancer
Interventions
DocetaxelDrug
75 mg/m2, d1, q3w,6 cycles
CarboplatinDrug
AUC 6, d1, q3w,6 cycles
TrastuzumabDrug
starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles
PertuzumabDrug
starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles
Nab paclitaxelDrug
220 mg/m2, d1, q3w,6 cycles
EpirubicinDrug
90 mg/m2, d1, q3w ,4 cycles ,followed by docetaxel
CyclophosphamideDrug
600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
DocetaxelDrug
100 mg/m2, d1, q3w × 4 cycles
EpirubicinDrug
90 mg/m2,d1, q2w × 4 cycles followed by nab-paclitaxel
CyclophosphamideDrug
600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
Nab paclitaxelDrug
125 mg/m2, d1,8,15, q3w× 4 cycles
CyclophosphamideDrug
600 mg/m2, d1, q3w × 6 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- 5-year DFSTime frame: 5-years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.